Trial to Test Precision Medicines for ARDS
UC San Francisco launches the PANTHER trial on Nov. 19, 2026, testing targeted drugs for acute respiratory distress syndrome.
Updated on Nov. 17, 2026 in Asthma

UC San Francisco will begin a clinical trial on Nov. 19, 2026, testing precision medicines for acute respiratory distress syndrome (ARDS). The PANTHER trial plans to enroll 300 patients at U.S. sites and will also run abroad.
Why it matters
ARDS affects 1 in 10 patients in intensive care units and is fatal for 35% to 45% of those affected, while current treatment is largely supportive care. The trial aims to match treatments to the biological form of the disorder, after earlier research found some treatments that helped one form showed no benefit when both were analyzed together.
The PANTHER trial enrolls 300 patients at 10 U.S. institutions, with one-third assigned to usual care only, and measures days alive without major life support over the first 28 days. Whether the trial's drugs will improve outcomes in either ARDS form remains unknown until results are reported.
The players
UC San Francisco
The University of California, San Francisco is a public research university and medical center based in San Francisco, California, known for its major clinical research programs.
U.S. Department of Defense
The Department of Defense is the federal agency responsible for the U.S. military, and it is funding the PANTHER trial.
The details
Patients receive a blood test for biomarkers that classify them as having hyperinflammatory or hypo-inflammatory ARDS, and are then assigned to treatment. The trial is funded by the U.S. Department of Defense and is designed as an adaptive platform, so promising new drugs can be added and ineffective ones dropped as evidence accumulates.
Timeline
Nov. 19, 2026: Clinical trial begins at UC San Francisco.
Over the first 28 days: The trial measures days patients live without major life support.
Big Picture
The PANTHER trial applies a biomarker-based classification to ARDS, moving away from one-size-fits-all supportive care toward subtype-specific drug testing. Its adaptive design, which adds promising drugs and drops ineffective ones, follows the platform model used in recent multi-arm trials.
For patients with ARDS, the trial offers access to drugs matched to their biomarker-defined form rather than only supportive care, though participation is limited to enrolled sites. Patients and families should discuss with their clinicians whether trial enrollment is an option during an ARDS hospitalization.
The takeaway
Precision matching of treatments to biological subtypes may be necessary before new ARDS drugs show a benefit. The PANTHER trial's design tests that idea directly across 300 patients.
Further reading
Explore more on Asthma for respiratory conditions and related research.
Source note: This article includes information reported by Home.










